Bausch Health Cos (NYSE:BHC) Upgraded at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Bausch Health Cos (NYSE:BHC) to a hold rating in a report released on Wednesday,Zacks.com reports.

Several other research analysts have also weighed in on BHC. Weiss Ratings lowered shares of Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 4th. Royal Bank Of Canada lowered their target price on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a research note on Monday, April 27th. Five research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $8.00.

Bausch Health Cos Trading Down 0.6%

NYSE:BHC opened at $4.42 on Wednesday. Bausch Health Cos has a 1-year low of $4.33 and a 1-year high of $8.69. The business’s 50-day moving average price is $5.00 and its two-hundred day moving average price is $5.55. The company has a current ratio of 1.32, a quick ratio of 0.97 and a debt-to-equity ratio of 54.68. The firm has a market capitalization of $1.66 billion, a price-to-earnings ratio of -1.37 and a beta of 0.42.

Bausch Health Cos (NYSE:BHC) last issued its earnings results on Wednesday, April 29th. The company reported $0.78 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.03). The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.37 billion. Bausch Health Cos had a negative return on equity of 2,922.77% and a negative net margin of 11.47%. On average, equities analysts expect that Bausch Health Cos will post 4.05 earnings per share for the current year.

Insider Activity at Bausch Health Cos

In other news, Director Frank D. Lee sold 24,456 shares of the business’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $5.43, for a total value of $132,796.08. Following the sale, the director owned 49,339 shares of the company’s stock, valued at $267,910.77. The trade was a 33.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Bausch Health Cos

Several hedge funds have recently modified their holdings of BHC. Dynamic Technology Lab Private Ltd bought a new stake in Bausch Health Cos during the first quarter worth about $68,000. Jones Financial Companies Lllp grew its stake in Bausch Health Cos by 1,548.9% in the first quarter. Jones Financial Companies Lllp now owns 24,965 shares of the company’s stock valued at $162,000 after purchasing an additional 23,451 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Bausch Health Cos by 97.1% in the first quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company’s stock valued at $6,136,000 after purchasing an additional 467,270 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Bausch Health Cos by 3.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 324,847 shares of the company’s stock worth $2,102,000 after purchasing an additional 9,834 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Bausch Health Cos by 11.2% during the 2nd quarter. Geode Capital Management LLC now owns 840,418 shares of the company’s stock worth $5,597,000 after purchasing an additional 84,892 shares during the last quarter. Institutional investors own 78.65% of the company’s stock.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.